drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (CAR-T)
drug_description
An autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy in which a patient's T cells are genetically engineered to express a CD19-specific CAR. CAR engagement activates CD3ΞΆ signaling with costimulation (e.g., CD28/4-1BB), leading to T-cell activation, proliferation, cytokine release, and cytotoxic killing of CD19-expressing B-cell leukemia cells.
nci_thesaurus_concept_id
C199061
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CD19-targeted chimeric antigen receptor; CD19 engagement activates CD3zeta and costimulatory (CD28/4-1BB) signaling, driving T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated killing of CD19-positive B-cell leukemia cells.
drug_name
Inaticabtagene autoleucel
nct_id_drug_ref
NCT06450067